Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren, moxonidine, hydrochlorothiazide, and placebo crossover trial in obesity-related hypertension
NL-OMON34298Phase 4Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of aliskiren, moxonidine and hydrochlorothiazide in hypertension (HTN) (4 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Change in endothelial function. Started Sep 2010; status: active, not recruiting.
02
Drugs
aliskirenmoxonidinehydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NL-OMON34298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34298.